Table 4.

Regional percent of Aβ deposition per year in a sample of subject with SCD (n = 168, dataset #3)

		Percent Aβ deposition per year
Method	Region	Aβ-negative	Gray zone	Established Aβ pathology
MRI-based ROIs	Frontal	− 0.01 ± 1.15 (p = 0.52)	1.08 ± 1.91 (p < 10−3)	2.72 ± 2.53 (p < 10−4)
	Lateral temporal	0.08 ± 0.99 (p = 0.21)	1.07 ± 1.61 (p < 10−4)	2.05 ± 2.18 (p < 10−3)
	Occipital	0.36 ± 1.13 (p < 10−3)	0.50 ± 1.74 (p = 0.38)	1.85 ± 2.18 (p < 10−3)
	Parietal	0.12 ± 1.29 (p = 0.16)	1.39 ± 2.10 (p = 0.02)	2.61 ± 2.28 (p < 10−5)
	Anterior cingulate	0.17 ± 1.81 (p = 0.13)	1.42 ± 2.12 (p = 0.10)	2.37 ± 3.07 (p = 0.001)
	Posterior cingulate	0.71 ± 1.72 (p < 10−5)	N.A	3.14 ± 2.46 (p < 10−7)
	Precuneus	0.31 ± 1.37 (p = 0.006)	N.A	N.A
	Composite	0.24 ± 1.24 (p = 0.02)	1.66 ± 1.86 (p < 10−3)	2.40 ± 2.37 (p < 10−3)
CL	Cortex	0.00 ± 0.89 (p = 0.53)	1.81 ± 1.86 (p < 10−3)	2.38 ± 1.82 (p < 10−4)

SCD subjective cognitive decline, N.A not available (As Aβ-negative, gray zone, and established Aβ pathology were defined regionally using cutoffs reported in Tables 2 and 3, there were not enough regional standardized uptake values (SUVRs) to calculate percent Aβ deposition per year in some regions), Aβ amyloid-beta, MRI magnetic resonance imaging, ROI region of interest, CL centiloid. p-values testing whether percent Aβ deposition per year is significantly larger than zero are given in parenthesis